pales
spent
nearli
four
decad
work
develop
univers
influenza
vaccin
would
replac
annual
immun
requir
flu
year
scientist
creat
updat
version
season
flu
vaccin
vaccin
target
hemagglutinin
head
accumul
mutat
pass
endless
chain
person
person
stalk
howev
less
variabl
pales
believ
decad
target
part
protein
could
form
basi
univers
flu
vaccin
nt
need
updat
everi
year
vision
univers
flu
vaccin
would
elicit
antibodi
react
hemagglutinin
stalk
mani
differ
strain
influenza
thu
neutral
wide
rang
strain
first
experi
toward
develop
hemagglutininstalkbas
vaccin
tri
answer
two
initi
question
could
vaccin
stimul
product
antistalk
antibodi
mice
could
antibodi
provid
protect
flu
pales
knew
immun
system
hard
time
gener
antibodi
stalk
head
physic
way
render
stalk
invis
vaccin
headless
hemagglutinin
protein
would
get
around
issu
initi
attempt
nt
pan
hope
protein
pales
colleagu
made
unstabl
yet
pales
still
believ
approach
although
one
knew
whether
human
could
even
stimul
produc
antibodi
hemagglutinin
stalk
pales
got
second
chanc
test
approach
year
new
strain
influenza
emerg
mexico
spread
around
world
pandem
swine
flu
viru
appear
even
season
flu
strain
continu
circul
arriv
swine
flu
pandem
provid
perfect
way
pales
test
whether
human
could
natur
produc
antibodi
hemagglutinin
stalk
although
season
swine
flu
strain
virus
hemagglutinin
head
virus
differ
antibodi
gener
season
flu
strain
nt
protect
swine
flu
even
though
stalk
broadli
similar
next
year
howev
season
flu
disappear
pandem
strain
becam
domin
pales
believ
antibodi
hemagglutinin
stalk
play
major
role
switch
mous
studi
support
hypothesi
exposur
differ
strain
influenza
trigger
product
antistalk
antibodi
research
identifi
potenti
segment
hemagglutinin
stalk
human
antibodi
might
work
publish
pna
pales
synthes
chimer
hemagglutinin
protein
show
infect
pandem
exposur
season
influenza
boost
product
hemagglutinin
stalk
sinc
season
fade
import
pales
knew
antistalk
antibodi
power
enough
protect
later
infect
result
pales
final
enough
data
suggest
approach
would
work
made
anoth
attempt
build
headless
hemagglutinin
univers
influenza
vaccin
creat
synthet
protein
consist
hemagglutinin
stalk
influenza
season
flu
virus
subsequ
switch
protect
mice
broader
rang
flu
virus
season
vaccin
also
death
diseas
togeth
krammer
pair
continu
refin
approach
engin
harmless
chimer
viru
mice
elicit
stalkspecif
antibodi
abl
target
broader
rang
influenza
strain
synthet
headless
hemagglutinin
make
strang
beast
could
show
could
redirect
immun
system
toward
conserv
region
viru
pales
say
group
scientist
tri
slightli
differ
approach
make
univers
flu
vaccin
eufund
multin
flutcor
project
combin
input
academ
scientist
pharmaceut
compani
synthes
noninfecti
viruslik
particl
yeast
incorpor
sever
influenza
antigen
includ
one
hemagglutinin
stalk
initi
studi
show
flutcor
approach
protect
mice
rang
influenza
group
current
rais
money
clinic
trial
meanwhil
pharmaceut
startup
biondvax
base
ness
ziona
israel
complet
phase
clinic
trial
univers
influenza
vaccin
vaccin
consist
singl
protein
built
nine
differ
small
protein
compon
includ
part
hemagglutinin
stalk
stimul
product
antibodi
protect
reaction
immun
system
coax
human
bodi
produc
antibodi
hemagglutinin
stalk
howev
first
step
long
road
bring
univers
flu
vaccin
market
stalkbas
influenza
vaccin
use
get
candid
readi
clinic
long
expens
process
krammer
say
take
year
prove
influenza
vaccin
protect
wide
varieti
strain
combin
high
safeti
season
vaccin
make
final
stage
trial
challeng
say
true
univers
vaccin
wait
pandem
hit
krammer
say
could
take
decad
pales
began
make
progress
stalkbas
vaccin
influenza
biochemist
jason
mclellan
watch
interest
lab
dartmouth
colleg
mclellan
special
coronavirus
larg
group
respiratori
pathogen
includ
virus
caus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
influenza
spike
protein
stud
coronaviru
membran
influenza
stalk
spike
protein
chang
far
slowli
fastevolv
head
got
mclellan
think
might
abl
tri
similar
approach
creat
stalkbas
coronaviru
vaccin
stalk
spike
protein
coronavirus
much
larger
hemagglutinin
stalk
influenza
larger
stalk
give
immun
system
target
point
gener
antibodi
mclellan
need
find
part
coronaviru
stalk
stimul
product
protect
antibodi
make
better
vaccin
use
monoclon
antibodi
individu
surviv
sar
mer
mclellan
virologist
mark
denison
vanderbilt
univers
identifi
part
coronaviru
spike
protein
like
elicit
immun
respons
research
turn
new
techniqu
enabl
flash
freez
differ
viral
particl
array
orient
bombard
particl
electron
use
supercomput
reconstruct
shape
resolut
four
angstrom
techniqu
known
singlemolecul
cryoelectron
microscopi
reveal
detail
shape
stalk
coronaviru
spike
protein
mclellan
could
use
guid
build
protein
subunit
vaccin
earli
headless
hemagglutinin
vaccin
attempt
pales
decad
ago
lop
head
spike
protein
use
stalk
alon
yield
protein
unstabl
vaccin
research
return
diagram
start
tweak
individu
amino
acid
creat
mer
coronaviru
vaccin
would
enough
stabil
elicit
strong
immun
respons
august
mclellan
colleagu
publish
paper
outlin
construct
stabl
engin
spike
glycoprotein
mer
although
team
yet
show
whether
protect
coronaviru
infect
differ
coronavirus
mani
similar
spike
glycoprotein
stem
give
mclellan
advantag
design
vaccin
coronavirus
huge
reservoir
coronavirus
wait
emerg
point
stalkbas
coronaviru
vaccin
may
even
protect
virus
yet
make
leap
human
thank
similar
stalk
coronaviru
spike
protein
design
stalkbas
vaccin
hiv
howev
stall
despit
year
effort
owe
part
viru
staggeringli
high
mutat
rate
although
virologist
speak
stalk
hiv
envelop
protein
env
conserv
rel
part
hiv
say
juli
overbaugh
immunologist
fred
hutchinson
cancer
research
center
seattl
compar
viral
protein
env
stalk
conserv
say
despit
mutabl
hiv
infect
individu
often
creat
broadli
neutral
antibodi
temporarili
hold
viru
check
analysi
antibodi
thousand
hivinfect
individu
reveal
five
target
broadli
neutral
antibodi
two
segment
env
stalk
follow
discoveri
scientist
develop
vaccin
target
loop
portion
lay
env
stalk
attempt
fizzl
fail
show
adequ
hiv
protect
anim
model
current
hiv
vaccin
develop
use
env
stalk
antigen
one
part
broader
strategi
accord
denni
burton
vaccinologist
scripp
research
institut
hiv
vaccin
probabl
look
lot
differ
vaccin
use
burton
say
current
vaccin
booster
consist
inject
initi
shot
burton
other
way
hiv
vaccin
like
requir
multipl
shot
slightli
differ
compon
time
persuad
immun
system
recogn
small
number
strain
thousand
ten
thousand
despit
mani
challeng
face
develop
stalkbas
vaccin
antivir
research
remain
convinc
strategi
eventu
pay
advantag
abil
target
wider
rang
virus
less
chanc
viru
mutat
therebi
make
vaccin
ultim
outweigh
time
expens
get
therapeut
readi
human
use
although
univers
flu
vaccin
closest
market
yet
complet
lengthi
phase
trial
whatev
final
result
process
creat
vaccin
help
open
research
eye
tremend
complex
interact
virus
human
immun
system
denison
say
work
alreadi
chang
scientist
thought
import
target
part
protein
like
stalk
provid
structur
well
bind
receptor
realli
excit
approach
say
point
mani
viral
protein
overlook
vaccin
target
nt
bind
receptor
work
stalkbas
vaccin
antivir
may
provid
approach
denison
call
broadli
applic
wide
varieti
virus
